Summary
16.37 0.17(1.05%)09/27/2024
Pieris Pharmaceuticals Inc (PIRS)
Pieris Pharmaceuticals Inc (PIRS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.30 | -5.05 | -7.88 | 72.68 | 8,364.32 | 5,404.37 | 353.46 | 495.27 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.37 | |
| Open | 16.59 | |
| High | 16.59 | |
| Low | 16.30 | |
| Volume | 26,183 | |
| Change | 0.21 | |
| Change % | 1.30 | |
| Avg Volume (20 Days) | 8,207 | |
| Volume/Avg Volume (20 Days) Ratio | 3.19 | |
| 52 Week Range | 0.14 - 18.68 | |
| Price vs 52 Week High | -12.37% | |
| Price vs 52 Week Low | 11,592.86% | |
| Range | -1.33 | |
| Gap Up/Down | -0.41 | |
Fundamentals | ||
| Market Capitalization (Mln) | 21 | |
| EBIDTA | -13,940,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 7.00 | |
| Book Value | 21.6370 | |
| Earnings Per Share | -21.6000 | |
| EPS Estimate Current Quarter | -0.1200 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | -0.3500 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | -21.6000 | |
| Revenues | ||
| Profit Marging | -0.5733 | |
| Operating Marging (TTM) | -4.2202 | |
| Return on asset (TTM) | -0.1476 | |
| Return on equity (TTM) | -0.8976 | |
| Revenue TTM | 42,810,000 | |
| Revenue per share TTM | 38.0260 | |
| Quarterly Revenue Growth (YOY) | -0.7780 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -27,080,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.6350 | |
| Revenue Enterprise Value | 0.5892 | |
| EBITDA Enterprise Value | 0.8971 | |
| Shares | ||
| Shares Outstanding | 1,236,690 | |
| Shares Float | 764,817 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 7.44 | |
| Institutions (%) | 38.89 | |
09/03 14:03 EST - businesswire.com
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.
08/16 15:42 EST - prnewswire.com
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. - PIRS
NEW YORK , Aug. 16, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS), relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
08/16 08:28 EST - globenewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
08/13 13:53 EST - globenewswire.com
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceutical s , Inc. ( Nasdaq : PIRS ) , relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Pieris Pharmaceutical s , Inc. ( Nasdaq : PIRS ) , relating to its proposed merger with Palvella Therapeutics, Inc. Under the terms of the agreement, Pieris shareholders are expected to own approximately 18% of the combined company.
07/24 14:55 EST - prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
07/24 12:16 EST - investorplace.com
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Pieris Pharmaceuticals (NASDAQ: PIRS ) stock is rocketing higher on Wednesday after announcing a merger agreement with Palvella Therapeutics. Pieris Pharmaceuticals and Palvella Therapeutics will enact an all-stock transfer for this merger.
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today?
Pieris Pharmaceuticals (NASDAQ: PIRS ) stock is rocketing higher on Wednesday after announcing a merger agreement with Palvella Therapeutics. Pieris Pharmaceuticals and Palvella Therapeutics will enact an all-stock transfer for this merger.
04/19 12:10 EST - accesswire.com
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol "PIRS".
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on April 22, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on April 23, 2024, under the Company's existing trading symbol "PIRS".
03/27 08:00 EST - accesswire.com
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® (antibody-Anticalin fusion) protein immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. After considering an extensive range of options, the Company's Board of Directors decided to implement this new strategy along with relevant cost-saving measures that are expected to extend the Company's cash runway into 2027.
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestones from its 4-1BB bispecific Mabcalin® (antibody-Anticalin fusion) protein immuno-oncology assets partnered with Pfizer (formerly Seagen), Boston Pharmaceuticals, and Servier. After considering an extensive range of options, the Company's Board of Directors decided to implement this new strategy along with relevant cost-saving measures that are expected to extend the Company's cash runway into 2027.
09/25 13:32 EST - zacks.com
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Why
Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
08/28 11:42 EST - pennystocks.com
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
08/25 11:06 EST - pennystocks.com
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
08/24 13:10 EST - pennystocks.com
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.
Best Penny Stocks To Buy Under $1.25? 3 To Watch Now
Are you looking for the best penny stocks to buy? You're not alone; many traders are showing a renewed interest in this exciting market.
08/23 13:32 EST - zacks.com
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know
Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
08/23 08:16 EST - zacks.com
New Strong Buy Stocks for August 23rd
JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023.
New Strong Buy Stocks for August 23rd
JHX, CWCO, GPI, CEG and PIRS have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2023.
08/22 10:51 EST - pennystocks.com
Penny Stocks To Buy This Week? 4 To Watch Under $5
If you're looking for penny stocks to buy this week, you've got your work cut out for yourself. Plenty of headwinds will be faced, including more tech earnings and Friday's speech from Fed Chair Jerome Powell.
Penny Stocks To Buy This Week? 4 To Watch Under $5
If you're looking for penny stocks to buy this week, you've got your work cut out for yourself. Plenty of headwinds will be faced, including more tech earnings and Friday's speech from Fed Chair Jerome Powell.
08/18 11:04 EST - zacks.com
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
08/17 08:00 EST - accesswire.com
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342 (formerly PRS-342), a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion (Mabcalin™) bispecific protein, which was discovered by Pieris and licensed to Boston Pharmaceuticals and designed to provide a potent costimulatory bridge to exert tumor killing activity through the recruitment of T-cells.
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals. The milestone is based on dosing the first patient in a Boston Pharmaceutical-sponsored phase 1/2 study of BOS-342 (formerly PRS-342), a 4-1BB/GPC3 immuno-oncology antibody-Anticalin fusion (Mabcalin™) bispecific protein, which was discovered by Pieris and licensed to Boston Pharmaceuticals and designed to provide a potent costimulatory bridge to exert tumor killing activity through the recruitment of T-cells.
08/16 07:58 EST - zacks.com
New Strong Buy Stocks for August 16th
GM, IBN, PIRS, GPI and MBWM have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2023.
New Strong Buy Stocks for August 16th
GM, IBN, PIRS, GPI and MBWM have been added to the Zacks Rank #1 (Strong Buy) List on August 16, 2023.
07/19 09:52 EST - zacks.com
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.
Pieris (PIRS) Pursues Strategic Alternatives, Stock Rises
Pieris (PIRS) announces strategic update after partner AstraZeneca terminated collaboration agreement and returned the rights to elarekibep.